Chronic kidney disease (CKD)
Anemia due to chronic kidney disease

PROCRIT® is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.

When treating anemia in CKD patients not on dialysis
Important dosing and administration information1
Consider initiating PROCRIT® treatment only when the Hb level is <10 g/dL and the following considerations apply:
  • The rate of Hb decline indicates the likelihood of requiring an RBC transfusion and
  • Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal
If the Hb level exceeds 10 g/dL, reduce or interrupt the PROCRIT® dose, and use the lowest PROCRIT® dose sufficient to reduce the need for RBC transfusions.
The recommended starting dose for adult patients is 50 U/kg to 100 U/kg three times weekly (TIW) IV or SC.
Flexible and individualized dosing options
Sample PROCRIT® starting dose for a 70-kg patient

50 U/kg TIW =
3,500 U TIW
  75 U/kg TIW =
5,250 U TIW
  100 U/kg TIW =
7,000 U TIW
Dosing algorithm for adults
A Range of Starting Dose Options

  • PROCRIT® is contraindicated in patients with uncontrolled hypertension, pure red cell aplasia (PRCA) that begins after treatment with PROCRIT® or other erythropoietin protein drugs, or severe allergic reactions to PROCRIT®. PROCRIT® from multidose vials contains benzyl alcohol and is contraindicated in neonates, infants, pregnant women, and nursing mothers
*Approximately 10,000 U, 15,000 U, or 20,000 U SC or IV used per week based on sample starting doses of 50 U/kg TIW, 75 U/kg TIW, or 100 U/kg TIW, respectively, for a 70-kg patient.

  1. PROCRIT® (epoetin alfa) Prescribing Information. Janssen Products, LP.
Indications and Important Safety Information
EXPAND    Expand ISI
Expand ISI
Important Safety Information
Expand ISI